RNA-seq of glioma patient-derived xenografts treated by DMSO or LY2109761

We employed the patient-derived xenografts (PDX) model to test the efficiency of LY2109761 in vivo. The drug was intraperitoneally administered, and the mice were sacrificed on the 31st day. The tumors were excised and subjected to RNA-seq. All groups had similar expression density distributions. Hierarchical clustering showed that the same processing groups had the closest distances. Examination of differential expressive genes in glioma tissues from PDX treated by DMSO or LY2109761.